Trial Profile
A dose-finding study of the safety and tolerability of intravenous reovirus (REOLYSIN) (pelareorep) plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with standard of care chemoradiotherapy (CTRT) /adjuvant chemotherapy for Glioblastoma Multiforme (GBM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Pelareorep (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms ReoGlio
- 13 Apr 2022 Results of Long term follow up, presented at the 113th Annual Meeting of the American Association for Cancer Research
- 08 Apr 2022 Results published in the Oncolytics Biotech Media Release.
- 08 Apr 2022 According to an Oncolytics Biotech media release, long-term survival data from the trial is being presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting.